Population Pharmacokinetic and Exposure-Safety Analyses of Ibrutinib for the Treatment of Chronic Graft-Versus-Host Disease.

Ogawa, Tetsuro; Mita, Sachiko; Atluri, Harisha; Iwaki, Yuki

Ogawa, Tetsuro; Mita, Sachiko; Atluri, Harisha; Iwaki, Yuki.

Afiliação

Ogawa T; Clinical Pharmacology and Pharmacometrics, Research & Development, Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo, Japan.
Mita S; Clinical Pharmacology and Pharmacometrics, Research & Development, Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo, Japan.
Atluri H; Clinical Pharmacology and Pharmacometrics, Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Iwaki Y; Clinical Pharmacology and Pharmacometrics, Research & Development, Janssen Pharmaceutical K.K., Chiyoda-ku, Tokyo, Japan.

J Clin Pharmacol ; 63(5): 613-621, 2023 05.

Article em En | MEDLINE | ID: mdl-36597869

Assuntos

Síndrome de Bronquiolite Obliterante; Inibidores do Citocromo P-450 CYP3A; Humanos; Adenina/efeitos adversos; Inibidores do Citocromo P-450 CYP3A/farmacologia; Piperidinas/efeitos adversos; Piperidinas/farmacocinética; Piperidinas/uso terapêutico

Palavras-chave

chronic graft-versus-host disease; concomitant use of CYP3A inhibitors; exposure response; ibrutinib; population pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores do Citocromo P-450 CYP3A / Síndrome de Bronquiolite Obliterante Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google